argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Shots:
- The NMPA has granted approval to the sBLA of Vyvgart Hytrulo [1,000mg (5.6ml)/vial], a once-weekly SC injection, for treating adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
- Approval was based on the results from ADHERE trial for CIDP. Zai Lab recruited participants in Greater China and observed responses similar to trial outcomes carried out worldwide
- Study showed a reduction of 69% in relapse risk among Chinese patients, with clinical improvement in 78% of them, indicating the role of IgG autoantibodies in the disease. Safety and tolerability aligned with global trial results
Ref: argenx | Image: Zai Lab & argenx
Related News:- Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
